Acquisition of a triple quadrupole mass spectrometer for small molecule analysis

购买用于小分子分析的三重四极杆质谱仪

• 批准号: 8826268
• 负责人: MICHELLE A RUDEK
• 金额: $ 31.44万
• 依托单位: JOHNS HOPKINS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-04-15 至 2016-04-14
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8826268
• 关键词: Acquired Immunodeficiency Syndrome; Antineoplastic Agents; Biomedical Research; Brain Neoplasms; Cancer Center; Cancer Patient; Clinical; Clinical Investigator; Clinical Trials; Comprehensive Cancer Center; Conduct Clinical Trials; Contracts; Coupled; Development; Equipment; Funding; Goals; Grant; Institution; Laboratories; Malignant Neoplasms; Minor; Pharmacology; Qualifying; Research; Research Personnel; Research Project Grants; Resource Sharing; Resources; Running; Services; Staging; System; Technical Expertise; Time; United States National Institutes of Health; Universities; experience; inhibitor/antagonist; instrument; liquid chromatography mass spectrometry; mass spectrometer; pre-clinical; pre-clinical research; rapid growth; small molecule

 DESCRIPTION (provided by applicant): The overall goal of this proposal is to acquire funds to purchase a triple quadrupole mass spectrometer to replace a recently decommissioned 11.5-year old Applied Biosystems (AB) SCIEX API3000 Triple Quad LC instrument. The funds will be used to purchase an AB SCIEX Triple Quad" 4500 system (a tandem quadrupole mass spectrometer) coupled with a Shimadzu Nexera UHPLC chromatographic system that will be dedicated to support NIH-funded investigators requiring quantitative analysis. A group of investigators at the Johns Hopkins and Mid-Atlantic Shared Resources Consortium Institutions (4 major, 3 minor) has been identified whose research (100% NIH-funded) is dependent on analyses which are only possible with the requested instrument. The Johns Hopkins University Sidney Kimmel Comprehensive Cancer Center (JHU SKCCC) is a NCI-Designated Comprehensive Cancer Center since 1976. The JHU SKCCC Analytical Pharmacology Core (JHU APC) is a Cancer Center shared resource that provides funded investigators with technical expertise and access to large equipment for quantitative analysis of anticancer drugs and related compounds. The JHU APC is used heavily by NIH-funded grants supporting the conduct of clinical trials in cancer patients with promising new therapies (UM1), AIDS malignancies (U01), with brain tumors (UM1) or late-stage development (U10). The JHU APC also supports preclinical research projects, e.g., preclinical development of GCPII inhibitors (R01) and preclinical projects from SPOREs (P50s) and the Mid-Atlantic Shared Resource Consortium (P30s). As the JHU APC supports both early clinical development of anti-cancer drugs and pre-clinical cancer-related research, it is a critical resource for the Cancer Center and the Johns Hopkins and Mid-Atlantic Shared Resource Consortium (MASRC) Institutions. This critical resource has experienced a rapid growth in the number of basic and clinical investigators requiring analytical services. As a result, usage of the existing LC/MS/MS instrument is currently at full capacity. An API3000 was fully decommissioned in December 2013 after over 11.5 years of service since ABSciex made the API3000 product line obsolete by ceasing to provide service and replacement parts for this instrument. Therefore, the capacity of the JHU APC has decreased substantially (by ~33%) until a qualified new mass spectrometer is functionally up and running in our laboratory. The addition of a new LC/MS/MS to replace the outdated LC/MS/MS will directly benefit NIH grant-funded early clinical trial and preclinical projects. In addition, it will indirectly benefit NIH-funded contracts and studies that are not currently NIH funded by freeing time on the existing LC/MS/MS. The LC/MS/MS capability of the JHU APC will contribute to the long-range biomedical research goals of the Johns Hopkins and Mid-Atlantic Shared Resource Consortium (MASRC) Institutions

 描述(申请人提供)：这项建议的总体目标是获得资金购买一台三重四极杆质谱仪，以取代最近退役的已有11.5年历史的应用生物系统(AB)SCIEX API3000三重四极LC仪器。这笔资金将用于购买AB SCIEX Triple Quad“4500系统(串联式四极质谱计)和岛津Nexera超高效液相色谱系统，该系统将专门为需要定量分析的NIH资助的调查人员提供支持。约翰霍普金斯大学和中大西洋共享资源联盟机构(4个主要机构，3个次要机构)的一组调查人员已经确定，他们的研究(100%由美国国立卫生研究院资助)依赖于只能使用所要求的仪器才能进行的分析。约翰霍普金斯大学西德尼·基梅尔综合癌症中心(JHU SKCCC)自1976年以来一直是美国国立卫生研究院指定的综合癌症中心。JHU SKCCC分析药理学核心(JHU APC)是癌症中心的共享资源，为受资助的研究人员提供技术专长并访问大型设备，用于抗癌药物和相关化合物的定量分析。美国国立卫生研究院资助的赠款大量使用JHU APC，支持对有前景的新疗法(UM1)、艾滋病恶性肿瘤(U01)、脑瘤(UM1)或晚期开发(U10)的癌症患者进行临床试验。JHU APC还支持临床前研究项目，例如GCPII抑制剂的临床前开发(R01)，以及来自孢子的临床前项目(P50)和中大西洋共享资源联盟(P30)。由于JHU APC支持抗癌药物的早期临床开发和临床前癌症相关研究，它是癌症中心和 约翰霍普金斯大学和中大西洋共享资源联盟(MASRC)机构。这一关键资源经历了需要分析服务的基础和临床研究人员数量的快速增长。因此，现有的LC/MS/MS仪器目前已满负荷使用。API3000在服役超过11.5年后于2013年12月完全退役，原因是ABSciex停止为该仪器提供服务和更换部件，从而使API3000产品线过时。因此，JHU APC的容量已大幅减少(~33%)，直到合格的新质谱计在我们实验室功能启动和运行。添加新的LC/MS/MS以取代过时的LC/MS/MS将直接使NIH拨款资助的早期临床试验和临床前项目受益。此外，JHU APC的LC/MS/MS能力将有助于约翰霍普金斯大学和中大西洋共享资源联盟(MASRC)机构的长期生物医学研究目标。此外，它还将间接受益于NIH资助的合同和研究，通过腾出现有LC/MS/MS的时间来资助这些合同和研究